Actelion Follows Innovation into GP Markets
Actelion has become Europe's most successful R&D-based biotech largely on the success of Tracleer for PAH, a specialist indication. Now, facing competition in PAH, but in line with its strategy of following innovation wherever it leads, the company's starting to build a primary care-focused commercial operation to support GP-targeted pipeline assets. That takes Actelion into a very new game, and risks destroying the laissez-faire culture seen as crucial to its unusually high R&D productivity. But Actelion reckons a well-planned, step-wise, and nimble approach to primary care marketing will allow it to retain both the maximum value from its drugs, and its biotech-ness.
You may also be interested in...
Although Pfizer Inc. and Gilead Sciences can be found at its margins, the pulmonary arterial hypertension space largely is a two-company competition. Currently, the two main players – United Therapeutics Corp. and Switzerland's Actelion Ltd. – have staked out a competitive advantage in a different portion of the space, but they are about to compete directly.
The Swiss biotech continues to defend its independence, appeasing investors with promise of regular dividends.
Hedge fund Elliott Advisors calls for Actelion CEO to quit the board, declaring a sale of the group to be in shareholders' best interests